BIENAIME JEAN JACQUES purchased $493K of ASND
BIENAIME JEAN JACQUES purchased 2,000 shares of Ascendis Pharma A/S (ASND) at an average of $246.33 ($245.85–$246.91, $0.49M total) across 2 trades on 2026-08-14.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market purchase of 2,000 shares at an average price of $246.3270, with holdings after the transaction of 2,900 shares.
Market read
Traders may treat the insider buy as a small sentiment input, but there is no accompanying earnings, trial, or regulatory catalyst in the text.
What to watch
The filing notes no 10b5-1 plan, but it still does not disclose the insider’s rationale, whether the purchase was opportunistic, or whether other insiders/large holders acted similarly.
Background
This is an SEC Form 4 insider transaction disclosure for Ascendis Pharma A/S, reported by a director.
Ticker impact
Ascendis Pharma director Bienaime Jean Jacques bought about 2,000 shares in open-market trades at roughly $245.85 to $246.91 on 2026-08-14.
Likely limited near-term impact; any effect is sentiment-driven and typically small versus earnings, guidance, or trial/regulatory news.
Insider purchases can signal confidence, but this filing provides no new company-specific operational or financial information, and the transaction is modest relative to typical market-moving events.
Market effects
Minimal. Insider buying in a single biotech does not materially change sector fundamentals without accompanying trial, regulatory, or guidance updates.
Minimal.
Minimal.
Counterpoint
Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect a change in near-term fundamentals.
Key entities
- issuerAscendis Pharma A/S
Subject of the Form 4 insider transaction disclosure.
- insiderBIENAIME JEAN JACQUES
Director who reported the open-market purchase.
